GRAIL reported a 28% increase in total revenue to $40.8 million for Q1 2026, driven by a 37% rise in Galleri test revenue and a 50% increase in test volume to over 56,000. The company plans to integrate its Galleri cancer detection test into Epic's electronic health record platform to expand nationwide access by the end of 2026. Despite a net loss of $93.2 million, GRAIL improved its financial performance compared to last year and will present new clinical data at the 2026 ASCO Annual Meeting. This integration and ongoing clinical validation aim to boost adoption and early cancer detection capabilities.
McDonald's Corporation offers a high-margin franchising model backed by prime real estate ownership, not just food sales. The stock trades at 21 times expected 2026 earnings, below its eight-year average, with a 2.8% dividend yield supported by stron...
Allegion reported strong second-quarter results, driven by broad growth in its Americas segment across residential and nonresidential markets, achieving a 30.1% adjusted operating margin. The company raised its full-year guidance, supported by a dura...
Strategy claims its current capital structure can sustain interest payments and preferred stock dividends even if Bitcoin falls 11.4% annually for 5.8 years. The company holds 843,775 BTC and $3.225 billion in cash reserves to support obligations tot...
Michael Saylor, CEO of Strategy, released a 953-hour reading curriculum covering history, economics, war, technology, and Bitcoin to train future leaders on understanding Bitcoin deeply. His program includes classics like The Story of Civilization an...
Hyperliquid has used $1.2 million of its revenue to burn 20.64K HYPE tokens as part of its deflationary strategy to control supply and support the token price, which remains below $60. Since August 2025, the project has generated $800 million in net ...
